Do analysts prefer QNRX or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, QNRX or BBLG?

Bone Biologics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quoin Pharmaceuticals N/A N/A -$15.81M -$29.56 N/A Bone Biologics N/A N/A -$3.11M -$2.27 N/A

Is QNRX or BBLG more profitable?

Bone Biologics' return on equity of -50.47% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Quoin Pharmaceuticals N/A -489.85% -221.29% Bone Biologics N/A -50.47% -47.40%

Do analysts recommend ALUR or BBLG?

Allurion Technologies currently has a consensus target price of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Allurion Technologies is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate HSCS or BBLG?

HeartSciences currently has a consensus price target of $8.00, indicating a potential upside of 225.20%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, HSCS or BBLG?

HeartSciences is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartSciences N/A N/A -$8.77M -$4.94 N/A Bone Biologics N/A N/A -$3.11M -$2.27 N/A

Is HSCS or BBLG more profitable?

Bone Biologics' return on equity of -50.47% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -333.50% -140.18% Bone Biologics N/A -50.47% -47.40%

Do analysts rate NXL or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer MBAI or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, MBAI or BBLG?

Check-Cap is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Check-Cap N/A N/A $4.14M -$2.01 N/A Bone Biologics N/A N/A -$3.11M -$2.27 N/A

Is MBAI or BBLG more profitable?

Check-Cap's return on equity of 0.00% beat Bone Biologics' return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Bone Biologics N/A -50.47% -47.40%

Bone Biologics (BBLG) Competitors

$1.11 -0.01 (-0.89%)

Closing price 03:59 PM Eastern

Extended Trading

$1.14 +0.02 (+2.25%)

As of 04:24 PM Eastern

Compare

BBLG vs. QNRX, ALUR, HSCS, NXL, and MBAI

Should you buy Bone Biologics stock or one of its competitors? MarketBeat compares Bone Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bone Biologics include Quoin Pharmaceuticals (QNRX), Allurion Technologies (ALUR), HeartSciences (HSCS), Nexalin Technology (NXL), and Check-Cap (MBAI). These companies are all part of the "medical equipment" industry.

How does Bone Biologics compare to Quoin Pharmaceuticals?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Bone Biologics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

In the previous week, Quoin Pharmaceuticals' average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
Quoin Pharmaceuticals	Neutral
Bone Biologics	Neutral

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 11.2% of Quoin Pharmaceuticals shares are held by insiders. Comparatively, 5.6% of Bone Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quoin Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Bone Biologics' return on equity of -50.47% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Bone Biologics	N/A	-50.47%	-47.40%

Summary

Quoin Pharmaceuticals and Bone Biologics tied by winning 5 of the 10 factors compared between the two stocks.

How does Bone Biologics compare to Allurion Technologies?

Allurion Technologies (NYSE:ALUR) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by company insiders. Comparatively, 5.6% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Allurion Technologies currently has a consensus target price of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Allurion Technologies is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bone Biologics has lower revenue, but higher earnings than Allurion Technologies. Bone Biologics is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

Bone Biologics has a net margin of 0.00% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat Bone Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Bone Biologics	N/A	-50.47%	-47.40%

Allurion Technologies has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

In the previous week, Allurion Technologies' average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
Allurion Technologies	Neutral
Bone Biologics	Neutral

Summary

Allurion Technologies beats Bone Biologics on 8 of the 13 factors compared between the two stocks.

How does Bone Biologics compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

HeartSciences has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

HeartSciences is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

In the previous week, HeartSciences had 2 more articles in the media than Bone Biologics. MarketBeat recorded 2 mentions for HeartSciences and 0 mentions for Bone Biologics. HeartSciences' average media sentiment score of 0.49 beat Bone Biologics' score of 0.00 indicating that HeartSciences is being referred to more favorably in the media.

Company	Overall Sentiment
HeartSciences	Neutral
Bone Biologics	Neutral

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 5.6% of Bone Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bone Biologics' return on equity of -50.47% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-333.50%	-140.18%
Bone Biologics	N/A	-50.47%	-47.40%

HeartSciences currently has a consensus price target of $8.00, indicating a potential upside of 225.20%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bone Biologics beats HeartSciences on 7 of the 13 factors compared between the two stocks.

How does Bone Biologics compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Nexalin Technology had 2 more articles in the media than Bone Biologics. MarketBeat recorded 2 mentions for Nexalin Technology and 0 mentions for Bone Biologics. Nexalin Technology's average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
Nexalin Technology	Neutral
Bone Biologics	Neutral

Bone Biologics has lower revenue, but higher earnings than Nexalin Technology. Nexalin Technology is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	35.29	-$8.22M	-$0.47	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by company insiders. Comparatively, 5.6% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nexalin Technology has a beta of 4, indicating that its share price is 300% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Bone Biologics has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Bone Biologics' return on equity of -50.47% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
Bone Biologics	N/A	-50.47%	-47.40%

Summary

Bone Biologics beats Nexalin Technology on 6 of the 11 factors compared between the two stocks.

How does Bone Biologics compare to Check-Cap?

Check-Cap (NASDAQ:MBAI) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Check-Cap's return on equity of 0.00% beat Bone Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Bone Biologics	N/A	-50.47%	-47.40%

In the previous week, Check-Cap had 1 more articles in the media than Bone Biologics. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for Bone Biologics. Check-Cap's average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
Check-Cap	Neutral
Bone Biologics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 5.6% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Check-Cap is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.01	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

Summary

Check-Cap beats Bone Biologics on 5 of the 9 factors compared between the two stocks.

Get Bone Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBLG vs. The Competition

Export

Metric	Bone Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.00M	$3.66B	$6.82B	$12.42B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.49	20.80	27.00	24.20
Price / Sales	N/A	322.97	519.38	94.43
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.37	8.17	10.67	6.26
Net Income	-$3.11M	$23.81M	$3.60B	$331.76M
7 Day Performance	-11.90%	-1.12%	-0.32%	-1.10%
1 Month Performance	-23.97%	2.64%	1.88%	-1.26%
1 Year Performance	-62.75%	45.50%	25.50%	18.84%

Bone Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBLG Bone Biologics	0.4591 of 5 stars	$1.11 -0.9%	N/A	-60.8%	$2.00M	N/A	N/A	2
QNRX Quoin Pharmaceuticals	0.4113 of 5 stars	$4.67 -1.1%	N/A	-50.4%	$9.48M	N/A	N/A	4
ALUR Allurion Technologies	N/A	$0.58 flat	$45.00 +7,658.6%	-98.8%	$8.70M	$17.21M	N/A	501
HSCS HeartSciences	2.1152 of 5 stars	$2.68 -1.8%	$8.00 +198.5%	-34.4%	$8.69M	N/A	N/A	10	Positive News Upcoming Earnings Gap Down
NXL Nexalin Technology	0.1195 of 5 stars	$0.45 +8.9%	N/A	-54.9%	$8.54M	$300K	N/A	3	News Coverage Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBLG) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bone Biologics (BBLG) Competitors

BBLG vs. QNRX, ALUR, HSCS, NXL, and MBAI

How does Bone Biologics compare to Quoin Pharmaceuticals?

Summary

How does Bone Biologics compare to Allurion Technologies?

Summary

How does Bone Biologics compare to HeartSciences?

Summary

How does Bone Biologics compare to Nexalin Technology?

Summary

How does Bone Biologics compare to Check-Cap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bone Biologics (BBLG) Competitors

BBLG vs. QNRX, ALUR, HSCS, NXL, and MBAI

How does Bone Biologics compare to Quoin Pharmaceuticals?

Which has preferable earnings & valuation, QNRX or BBLG?

Does the media refer more to QNRX or BBLG?

Do insiders & institutionals have more ownership in QNRX or BBLG?

Do analysts prefer QNRX or BBLG?

Which has more risk and volatility, QNRX or BBLG?

Is QNRX or BBLG more profitable?

Summary

How does Bone Biologics compare to Allurion Technologies?

Do institutionals & insiders believe in ALUR or BBLG?

Do analysts recommend ALUR or BBLG?

Which has stronger valuation & earnings, ALUR or BBLG?

Is ALUR or BBLG more profitable?

Which has more volatility and risk, ALUR or BBLG?

Does the media favor ALUR or BBLG?

Summary

How does Bone Biologics compare to HeartSciences?

Which has more risk and volatility, HSCS or BBLG?

Which has stronger earnings & valuation, HSCS or BBLG?

Does the media favor HSCS or BBLG?

Do institutionals and insiders believe in HSCS or BBLG?

Is HSCS or BBLG more profitable?

Do analysts rate HSCS or BBLG?

Summary

How does Bone Biologics compare to Nexalin Technology?

Does the media favor NXL or BBLG?

Which has better valuation & earnings, NXL or BBLG?

Do analysts rate NXL or BBLG?

Do institutionals & insiders believe in NXL or BBLG?

Which has more volatility and risk, NXL or BBLG?

Is NXL or BBLG more profitable?

Summary

How does Bone Biologics compare to Check-Cap?

Is MBAI or BBLG more profitable?

Does the media favor MBAI or BBLG?

Do analysts prefer MBAI or BBLG?

Which has more risk and volatility, MBAI or BBLG?

Do insiders & institutionals believe in MBAI or BBLG?

Which has stronger earnings and valuation, MBAI or BBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools